ArticleCell death & disease2020
Galectin-3 deficiency in pregnancy increases the risk of fetal growth restriction (FGR) via placental insufficiency.
Article in Cell death & disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 56 citations in OpenAlex.
- Galectin-Levels Are Elevated in Infants Born Preterm Due to Amniotic Infection and Rapidly Decline in the Neonatal Period.Frontiers in immunology · 2020Trial
- Select Histochemical and Immunohistochemical Methods to Investigate the Cell and Tissue Composition of the Mouse Placenta and Metrial Gland.Toxicologic pathology · 2026Review
- Article
- Abnormal Galectin Signaling in the Pathomechanisms of Placental Dysfunction in Gestational Diabetes Mellitus.International journal of molecular sciences · 2026Review
- Comparative analysis of inflammatory and metabolic biomarkers in PGDM and GDM pregnancies.BMC pregnancy and childbirth · 2025Article
- Galectin-3 in endometrial small extracellular vesicles promotes cytotrophoblast cell fusion during the implantation phase.Cell communication and signaling : CCS · 2025Article
- Mapping the placental galectin-3 interactome identifies CD9 and ITGB1 as functional glycoprotein counterreceptors during syncytialization.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Immune checkpoint for pregnancy.Seminars in immunopathology · 2025Review
- Focus on Cell Apoptosis, Pyroptosis and Ferroptosis to Explore Strategic Breakthrough for GDM.Journal of inflammation research · 2025Review
- Article
- Bridging the Gap between Galectin-3 Expression and Hypertensive Pregnancy Disorders: A Narrative Review.Journal of clinical medicine · 2024Review
- Fetal growth restriction induced by maternal gal-3 deficiency is associated with altered gut-placenta axis.Cell death & disease · 2024Article
- First Trimester Placental Biomarkers for Pregnancy Outcomes.International journal of molecular sciences · 2024Review
- Genetic Associations of Circulating Cardiovascular Proteins With Gestational Hypertension and Preeclampsia.JAMA cardiology · 2024Article
- In utero pulse injection of isotopic amino acids quantifies protein turnover rates during murine fetal development.Cell reports methods · 2024Article
- Galectin-3 plays a key role in controlling infection byFrontiers in cellular and infection microbiology · 2024Article
- Effects of Gestational Arsenic Exposures on Placental and Fetal Development in Mice: The Role ofEnvironmental health perspectives · 2023Article
- Elevated galectin-3 levels detected in women with hyperglycemia during early and mid-pregnancy antagonizes high glucose - induced trophoblast cells apoptosis via galectin-3/foxc1 pathway.Molecular medicine (Cambridge, Mass.) · 2023Article
- Article
- Roles of N-linked glycosylation and glycan-binding proteins in placentation: trophoblast infiltration, immunomodulation, angiogenesis, and pathophysiology.Biochemical Society transactions · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fetal growth restriction (FGR) is the most common pregnancy complication in developed countries. Pregnancies affected by FGR, frequently concur with complications and high risk of neonatal morbidity and mortality. To date, no approved treatment is available for pregnant women affected with FGR. The objective of this study was to investigate the contribution of galectin-3 (gal-3), a β-galactoside binding protein involved in pregnancy, placental function and fetal growth. We demonstrated that lack of gal-3 during mouse pregnancy leads to placental dysfunction and drives FGR in the absence of a maternal preeclampsia syndrome. Analysis of gal-3 deficient dams revealed placental inflammation and malperfusion, as well as uterine natural killer cell infiltration with aberrant activation. Our results also show that FGR is associated with a failure to increase maternal circulating gal-3 levels during the second and third trimester in human pregnancies. Placentas from human pregnancies affected by FGR displayed lower gal-3 expression, which correlated with placental dysfunction. These data highlight the importance of gal-3 in the promotion of proper placental function, as its absence leads to placental disease and subsequent FGR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.